Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

BACKGROUND: In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who...

全面介紹

Na minha lista:
書目詳細資料
發表在:Lancet Oncol
Main Authors: Friedlander, Michael, Gebski, Val, Gibbs, Emma, Davies, Lucy, Bloomfield, Ralph, Hilpert, Felix, Wenzel, Lari B, Eek, Daniel, Rodrigues, Manuel, Clamp, Andrew, Penson, Richard T, Provencher, Diane, Korach, Jacob, Huzarski, Tomasz, Vidal, Laura, Salutari, Vanda, Scott, Clare, Nicoletto, Maria Ornella, Tamura, Kenji, Espinoza, David, Joly, Florence, Pujade-Lauraine, Eric
格式: Artigo
語言:Inglês
出版: 2018
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869962/
https://ncbi.nlm.nih.gov/pubmed/30026002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30343-7
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍